Predicta Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Predicta Biosciences - overview
Established
2023
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2023 by CEO Irene Ghobrial, CTO Ken Anderson, and co-founder Gad Getz, Predicta Biosciences, Inc. , operates as a healthtech company providing precision oncology for businesses that uses multiomics to create cutting-edge medical and diagnostic tools. In October 2025, Predicta Biosciences, Inc. raised USD 23.
4 million in series A funding led by returning investor Engine Ventures, with participation from new investors Lightchain Capital, Mass General Brigham Ventures, BrightEdge Ventures, Binney Street Capital, and Myeloma Investment Fund. Other unspecified and another returning investor Illumina Ventures also participated in the round. Predicta Biosciences, Inc. developed precision oncology for transforming diagnostic and therapeutic tools for the patients.
The company offers diagnostic products that eliminates invasive bone-marrow biopsies, instead utilizing small blood-based samples. The Predicta platform captures multi-omics and immune system data to build a clinical database. In addition, the firm provides artificial intelligence-based tools that mines the data to discover novel therapeutic targets and immune signatures. The company will use the October 2025 funding to expand its AI-driven drug discovery platform and grow its team.
Current Investors
Illumina Ventures, Engine Ventures, American Cancer Society
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.predictabiosciences.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.